Ranking Alexa Global: # 2,363,989
Server:Apache...
X-Powered-By:PleskLin
The main IP address: 80.247.175.20,Your server Netherlands,Winschoten ISP:Denit Internet Services TLD:com CountryCode:NL
The description :kiadis pharma...
This report updates in 16-Jun-2018
Created Date: | 2002-04-02 |
Changed Date: | 2017-04-02 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host kiadis.com. Currently, hosted in Netherlands and its service provider is Denit Internet Services .
Latitude: | 53.14416885376 |
Longitude: | 7.0347199440002 |
Country: | Netherlands (NL) |
City: | Winschoten |
Region: | Groningen |
ISP: | Denit Internet Services |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.
Content-Length: | 6990 |
X-Powered-By: | PleskLin |
Content-Encoding: | gzip |
Vary: | Accept-Encoding |
Keep-Alive: | timeout=5, max=100 |
Server: | Apache |
Connection: | Keep-Alive |
Date: | Fri, 15 Jun 2018 22:59:49 GMT |
Content-Type: | text/html; charset=UTF-8 |
X-Pingback: | http://www.kiadis.com/xmlrpc.php |
soa: | dns1.movenext.nl. hostmaster.movenext.nl. 2018041905 14400 3600 1209600 3600 |
txt: | "MS=ms77356633" "v=spf1 include:spf.protection.outlook.com ip4:89.207.31.250/32 ip4:89.207.31.251/32 a:fortimail.netdata.nl ip4:95.155.191.58 -all" |
ns: | dns2.movenext.net. dns1.movenext.nl. |
ipv4: | IP:80.247.175.20 ASN:25542 OWNER:DENIT-AS Amsterdam, NL Country:NL |
mx: | MX preference = 10, mail exchanger = kiadis-com.mail.protection.outlook.com. |
contact careers legal about us company overview management team supervisory board partners and advisors company presentation may 2018 our focus overview graft-versus-host disease (gvhd) leukemia products & technology overview atir101 for investors overview kiadis pharma raises €23.4 million in private placement summary and securities note private placement march 12, 2018 registration document march 2018 company presentation may 2018 stock information shareholders’ meetings financial reports and presentations corporate governance major shareholders for healthcare professionals news and events news events in the media kiadis pharma receives fda regenerative medicine advanced therapy (rmat) designation for atir101™ the us food and drug administration (fda) has granted atir101™, kiadis pharma’s lead investigational product for blood cancers, the regenerative medicine advanced therapy (rmat) designation. addressing the risks and limitations connected with stem cell transplantation kiadis pharma is focused on two therapeutic indications: leukemia and thalassemia. its products address the key risks and limitations of hematopoietic stem cell transplantation, including opportunistic infections, graft-versus-host-disease, cancer relapse and limited donor availability. atir (allodepleted t-cell immunotherapeutics): cellular products for infusion atir consists of donor lymphocytes specifically manufactured for individual patients where those t-cells from the haploidentical stem cell donor that can attack the patient are eliminated but the other donor immune cells are retained. atir solves the problem of not finding a matched donor in time. developing life-saving therapies for blood cancer patients and patients with inherited blood disorders kiadis pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. about us find out more about kiadis pharma, our history and our values disease areas kiadis pharma is developing innovative and potentially life‑saving therapies for patients with late-stage blood cancers and certain inherited blood disorders our technology kiadis pharma's technology and products address the key risks and limitations of hematopoietic stem cell transplantation atir atir101 is the company’s lead product and addresses the key risks and limitations of hsct in blood cancers kiadis pharma raises €23.4 million in private placement, march 13, 2018 view pricing press release view summary and securities note view launch press release view registration document -- annual results for the year ended december 31, 2017 view annual report view financial statement view presentation -- events holland bio 29, june, 2018, inn style, maarssen, the netherlands after the successful 2017 edition, holland […] read more news at kiadis pharma, we want to keep you informed of the latest company news, developments in our field, and let you know where you can meet us find out more contact us if you would like to know more about kiadis pharma, please contact us find out more follow us -- -- products & technology atir101 our technology company presentation the company presentation provides a valuable insight into where kiadis pharma stands today. company presentation contact us do you have questions about our website, our products or any of our services? get in touch contact sitemap legal disclaimer privacy cookies © 2018 kiadis pharma
http://www.kiadis.com///products/
http://www.kiadis.com/privacy/
http://www.kiadis.com/about/management-team/
http://www.kiadis.com///product/atir101/
http://www.kiadis.com/product/atir101/
http://www.kiadis.com/investors/corporate-governance/
http://www.kiadis.com///about/
http://www.kiadis.com/investors/stock-information/
http://www.kiadis.com/news-and-events/events/
http://www.kiadis.com///products/atir101/
http://www.kiadis.com/diseases/
http://www.kiadis.com/disease/graft-versus-host-disease-gvhd/
http://www.kiadis.com/investors/major-shareholders/
http://www.kiadis.com/contact/
http://www.kiadis.com/for-healthcare-professionals/
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain Name: KIADIS.COM
Registry Domain ID: 85102987_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.registrar.eu
Registrar URL: http://www.openprovider.com
Updated Date: 2017-04-02T10:08:06Z
Creation Date: 2002-04-02T11:40:27Z
Registry Expiry Date: 2018-04-02T10:40:27Z
Registrar: Hosting Concepts B.V. d/b/a Openprovider
Registrar IANA ID: 1647
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +31.104482297
Domain Status: ok https://icann.org/epp#ok
Name Server: DNS1.MOVENEXT.NL
Name Server: DNS2.MOVENEXT.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-10T00:26:05Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Hosting Concepts B.V. d/b/a Openprovider
SERVERS
SERVER com.whois-servers.net
ARGS domain =kiadis.com
PORT 43
TYPE domain
DOMAIN
NAME kiadis.com
CHANGED 2017-04-02
CREATED 2002-04-02
STATUS
ok https://icann.org/epp#ok
NSERVER
DNS1.MOVENEXT.NL 80.247.175.10
DNS2.MOVENEXT.NET 5.100.229.11
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .